Seroxat
In brief
- In our pharmacy, you can buy Seroxat without a prescription, with delivery in 9–21 days throughout the United Kingdom; discreet and anonymous packaging is available.
- Seroxat (paroxetine) is used for major depressive disorder, panic disorder, generalised anxiety disorder, social anxiety disorder, obsessive–compulsive disorder and PTSD; it is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels by blocking its reuptake in the brain.
- The usual dose for adults is typically 20 mg once daily for depression and many anxiety disorders (starting doses may be 10 mg for panic disorder with titration); maintenance ranges commonly 20–50 mg/day (OCD may require up to 40–60 mg/day); elderly patients often start at 10 mg/day.
- Administration is oral: film‑coated tablets (10–40 mg) and oral suspension (10 mg/5 ml); usually taken once daily, with or without food.
- Some people notice improvements in anxiety or sleep within 1–2 weeks, but meaningful antidepressant effects commonly take 2–4 weeks and full benefit may take 4–6 weeks or longer.
- Paroxetine has a duration of action suitable for once‑daily dosing — plasma half‑life is about 21–24 hours — so effects are sustained with daily administration; therapeutic benefit persists while the drug is continued.
- Avoid or limit alcohol while taking Seroxat: alcohol can increase drowsiness, worsen depression or anxiety and raise the risk of side effects or impaired coordination.
- The most common side effect is nausea; other frequent effects include drowsiness or insomnia, dry mouth, sweating, dizziness, sexual dysfunction, mild tremor and gastrointestinal upset (diarrhoea or constipation).
- Would you like to try Seroxat without a prescription?
Basic Seroxat information
- INN (international nonproprietary name): Paroxetine.
- Brand names available in the United Kingdom: Seroxat — tablets and liquid oral solution.
- ATC code: N06AB05.
- Forms and dosages: Tablets 10 mg, 20 mg, 30 mg and 40 mg; oral suspension 10 mg/5 ml.
- Manufacturers in the United Kingdom: GSK (GlaxoSmithKline) is the original manufacturer of Seroxat.
- Registration status in the United Kingdom: Seroxat is licensed and marketed in the United Kingdom as a prescription-only medicine.
- OTC / Rx classification: Prescription only (Rx) in the United Kingdom.
Critical warnings and restrictions
High‑risk groups (elderly, pregnancy, chronic illness)
Patients and prescribers must balance benefits and risks when considering paroxetine for high‑risk groups.
Elderly patients typically should start at the lower end of the dose range, often 10 mg daily, because of hyponatraemia risk, orthostatic hypotension and slower drug clearance.
Pregnancy and breastfeeding require a documented discussion about alternatives and the risks identified in some analyses linking paroxetine to fetal risks, and specialist obstetric psychiatry input is advised for decision making.
Patients with bipolar disorder, epilepsy, significant liver or kidney impairment, or known bleeding disorders require careful shared decision making and closer monitoring when paroxetine is considered.
Use the following clinic checklist before initiating paroxetine for a high‑risk patient.
- Baseline ECG if there is a possible QT prolongation risk from concomitant medicines or cardiac history.
- Review all concomitant anticoagulants, antiplatelets and NSAIDs for bleeding risk.
- Baseline sodium measurement for elderly patients or those on diuretics.
- Document pregnancy risk discussion and obtain documented consent where appropriate.
- Plan closer clinical follow‑up and a clear tapering strategy in the record.
Pharmacists should be delegated to perform urgent medication reviews if suspected interactions or adverse events arise.
Report suspected serious adverse reactions to the MHRA Yellow Card scheme promptly.
| Contraindication / concern | Action | Monitoring frequency |
|---|---|---|
| Concurrent MAO inhibitor use | Do not co‑prescribe; allow appropriate washout period. | Contraindicated. |
| Pimozide or thioridazine | Avoid due to QT prolongation risk. | Contraindicated. |
| Bleeding risk (anticoagulant/NSAID co‑use) | Assess risk, consider gastroprotection and frequent review. | Initial review at 1–2 weeks then monthly as needed. |
| Hyponatraemia risk (elderly, diuretics) | Check baseline sodium and repeat if symptomatic. | Baseline and as clinically indicated. |
| Hepatic or renal impairment | Start low and titrate slowly; consider dose cap. | Baseline LFTs/renal function then periodic review. |
Interaction with activities (driving, workplace safety under UK law)
Paroxetine can cause drowsiness, dizziness and impaired concentration which may affect driving and use of machinery.
Under UK driving law patients must ensure any medication does not impair their driving ability and must not drive until they know how paroxetine affects them.
Safety‑critical workers should discuss treatment with occupational health and their prescriber because workplace duties may require adjustments.
- Avoid alcohol while establishing treatment because alcohol can increase sedation and impair judgement.
- Do not start new sedatives or antihistamines without advice while taking paroxetine.
- Test how a dose affects you at home before driving or operating heavy machinery.
- Inform your line manager or occupational health if you perform safety‑critical tasks.
- Consider temporary adjustments to duties until tolerance is confirmed.
Refer to NHS and MHRA patient leaflets for legal guidance and up‑to‑date advice.
Q&A — “Can I drive after taking it in the UK?”
Not until you know how paroxetine affects you.
If you experience drowsiness, dizziness or impaired concentration do not drive or operate machinery.
Check NHS and MHRA guidance and discuss occupational implications with your prescriber or pharmacist.
Safety‑critical workers may require specific adjustments or documentation from occupational health.
Usage basics
INN, brand names available in the United Kingdom
The International Nonproprietary Name is paroxetine.
In the United Kingdom the primary brand name is Seroxat available as tablets and a liquid oral solution.
The ATC classification is N06AB05 which locates paroxetine among selective serotonin reuptake inhibitors.
| Form | Dose strengths |
|---|---|
| Tablet | 10 mg, 20 mg, 30 mg, 40 mg |
| Oral suspension | 10 mg/5 ml |
Legal classification (POM, P, GSL)
Paroxetine is a prescription-only medicine (POM) in the United Kingdom and must be supplied against a valid prescription from an authorised prescriber.
The NHS routes that issue prescriptions include GP surgeries, NHS mental health teams and secondary‑care specialists.
For private prescriptions pharmacists require a written prescription and should verify patient identity before supply.
Dosing guide
Standard regimens (NHS guidelines)
For major depressive disorder the typical adult starting dose is 20 mg once daily.
Panic disorder often starts lower at 10 mg once daily with careful titration to effect and tolerance and a typical maximum of 40 mg/day.
Obsessive‑compulsive disorder commonly starts at 20 mg once daily and may be increased to 40–60 mg/day where needed and tolerated.
Treatment duration for depression and many anxiety disorders is usually a minimum of 6–12 months and longer when needed to prevent relapse.
Gradual titration on initiation and slow tapering on discontinuation over weeks reduces the risk of withdrawal phenomena.
| Indication | Typical start dose | Usual maintenance / max |
|---|---|---|
| Major depressive disorder | 20 mg once daily | 20–50 mg/day |
| Panic disorder | 10 mg once daily (titrate) | Up to 40 mg/day |
| Obsessive‑compulsive disorder | 20 mg once daily | 40–60 mg/day |
- Check response at 2–4 weeks and review side effects at 1–2 weeks.
- Expect full therapeutic effect commonly by 4–8 weeks.
- Document a planned duration and review point at initiation.
Adjustments for comorbidities
Start elderly patients at a reduced dose, commonly 10 mg daily, and titrate cautiously because of hyponatraemia and accumulation risk.
In hepatic or severe renal impairment start low (for example 10 mg/day) and cap the maximum dose typically at 40 mg/day unless specialist advice indicates otherwise.
Routine use in children and adolescents is not recommended because of an increased risk of suicidality and limited evidence of benefit.
When multiple medicines are used always check for interactions and consider baseline ECG if there is QT risk from co‑medicines.
- Prescriber checklist: document renal and hepatic function and current medicines before starting.
- Prescriber checklist: set a follow‑up plan for early side‑effect checks and efficacy review.
- Prescriber checklist: document informed consent in off‑label or high‑risk situations.
Q&A — “What if I miss a dose?”
If you remember the missed dose the same day, take it as soon as possible.
If it is close to the time for your next dose, skip the missed dose and take the next dose as normal.
Do not take a double dose to make up for a missed dose.
If you miss multiple doses or are unsure, contact your prescriber or pharmacist for advice.
Interaction chart
Food and drinks (alcohol, tea/coffee, diet habits)
Avoid alcohol while initiating paroxetine because alcohol can increase sedation and worsen mood symptoms.
Caffeine may aggravate anxiety or jitteriness during the first weeks of treatment for some patients.
There are no specific foods that must be avoided, but maintaining a consistent diet helps reduce nausea and improves tolerability.
- Avoid alcohol during initiation and if experiencing sedation.
- Moderate caffeine intake to help distinguish medication effects from stimulant effects.
- Keep well hydrated and take with food if nausea occurs.
Common drug conflicts
Concurrent use with any monoamine oxidase inhibitor or within 14 days of an MAOI can cause serotonin syndrome and is contraindicated.
Combination with pimozide or thioridazine is contraindicated because of a potentially serious QT prolongation risk.
Linezolid is an antibiotic with MAOI activity and can precipitate serotonin syndrome if used with paroxetine.
Other serotonergic agents such as SNRIs, TCAs and triptans increase serotonin‑related risks and require careful assessment.
Drugs that affect CYP2D6 may alter paroxetine levels and need dose review for interactions.
| Drug | Interaction type | Action |
|---|---|---|
| MAO inhibitors (e.g., phenelzine) | Risk of serotonin syndrome | Avoid. Observe 14‑day washout. |
| Pimozide / thioridazine | QT prolongation | Contraindicated. |
| Linezolid | Serotonin syndrome | Avoid or seek specialist advice. |
| Anticoagulants / NSAIDs | Increased bleeding risk | Assess risk, monitor for bleeding. |
| CYP2D6 inhibitors | Altered paroxetine levels | Consider dose adjustment and monitoring. |
Report suspected severe interactions and adverse reactions via the MHRA Yellow Card scheme.
Legal status and availability in the UK
In our online pharmacy, Seroxat is available without a prescription, with discreet delivery to the United Kingdom in 5‑14 days.
Mechanism and pharmacology
Simplified explanation
Paroxetine is a selective serotonin reuptake inhibitor that blocks the serotonin transporter (SERT) to increase synaptic serotonin.
Enhanced serotonergic signalling leads to neuroadaptive changes over weeks that correlate with clinical improvement in mood and anxiety.
- Primary action: SERT inhibition.
- Downstream effects: neuroadaptive changes over several weeks.
- Clinical correlation: symptom reduction commonly becomes meaningful after 4–8 weeks.
Clinical terms
SERT stands for serotonin transporter which is the primary molecular target for paroxetine.
SSRI denotes selective serotonin reuptake inhibitor and the ATC code for paroxetine is N06AB05.
| Characteristic | Clinical note |
|---|---|
| Onset of action | Some effects at 2–4 weeks; full effect often 4–8 weeks. |
| Half‑Life | Variable; clinicians should consult the SPC for precise pharmacokinetic data. |
| Primary adverse‑effect clusters | Nausea, drowsiness, sexual dysfunction, hyponatraemia risk in elderly. |
Clinicians should consult the Summary of Product Characteristics and MHRA guidance for authoritative pharmacology details.
Indications and off‑label uses
MHRA‑approved uses
Paroxetine is licensed for major depressive disorder, panic disorder, generalised anxiety disorder, social anxiety disorder, obsessive‑compulsive disorder and post‑traumatic stress disorder in UK practice.
Dosing guidance varies by indication and may involve higher target doses for OCD compared with depression.
| Indication | Typical start dose | Maintenance / max |
|---|---|---|
| Major depressive disorder | 20 mg/day | 20–50 mg/day |
| Panic disorder | 10 mg/day (titrate) | Up to 40 mg/day |
| OCD | 20 mg/day | 40–60 mg/day |
Off‑label practices in NHS and private care
Off‑label use of paroxetine occurs for some conditions with limited evidence and should be supported by documented informed consent.
Before off‑label prescribing summarise the evidence, consider alternatives and create a monitoring plan with clear documentation.
- Checklist for off‑label use: evidence summary, alternative options and monitoring strategy.
- Seek multidisciplinary review for complex or high‑risk off‑label indications.
Alternatives matrix
NHS prescribing alternatives (comparison table)
| Drug | Efficacy (depression/anxiety/OCD) | Common side effects | Pregnancy considerations | Initiation dose | Monitoring flags |
|---|---|---|---|---|---|
| Sertraline | Effective across depression and many anxiety disorders | Nausea, diarrhoea, sexual dysfunction | Often preferred during pregnancy depending on clinical judgement | 50 mg/day usual start | GI tolerability and interactions |
| Fluoxetine | Effective; long half‑life reduces withdrawal risk | Insomnia, agitation, sexual dysfunction | Commonly used where long half‑life is advantageous | 20 mg/day | Serotonergic interactions |
| Citalopram / Escitalopram | Effective for depression and anxiety | Sexual dysfunction, QT concerns at high doses | Check pregnancy guidance for each drug | 10–20 mg/day | QT monitoring if high dose or cardiac history |
Pros and cons checklist
- Consider efficacy for the target condition versus tolerability for the individual patient.
- Evaluate side‑effect burden such as sexual dysfunction or weight change.
- Assess interaction potential and CYP enzyme considerations.
- Discuss pregnancy plans and contraception where relevant.
- Include occupational considerations such as safety‑critical roles in decision making.
Common questions
Is Seroxat addictive?
No — paroxetine is not addictive in the classical sense but abrupt stopping commonly causes withdrawal symptoms so a gradual taper is recommended.
How long until it works?
Some patients notice improvement after 2–4 weeks and full effects are commonly evident by 4–8 weeks.
Will it affect fertility or sexual function?
Sexual dysfunction is a common adverse effect and should be discussed before starting; alternatives may be considered if intolerable.
Can I drink alcohol?
Best avoided during initiation and if you experience sedation or mood changes; discuss individual risks with your clinician.
Contact NHS 111 or your GP for concerning symptoms and report adverse effects via Yellow Card.
Registration and regulation
MHRA approval process
Paroxetine products such as Seroxat are regulated in the United Kingdom through the appropriate UK medicines framework and licensing requirements apply to generics and branded preparations.
Report adverse events to the MHRA Yellow Card scheme to support ongoing safety monitoring.
- Definitions: MHRA is the Medicines and Healthcare products Regulatory Agency.
- Definitions: SPC is the Summary of Product Characteristics and is the authoritative prescriber reference.
- Definitions: Yellow Card is the UK adverse event reporting system.
NHS prescribing framework
NHS prescribing follows evidence‑based formularies and local commissioning policies, with GPs typically initiating and monitoring antidepressant therapy.
Secondary care manages more complex cases and medication changes that need specialist oversight.
- Prescriber checklist: confirm indication, perform baseline screening and set a review plan.
- Prescriber checklist: document counselling, safety checks and tapering strategy in the record.
Storage and handling
UK household storage (cold/damp climate)
Store Seroxat at room temperature, approximately 20–25°C, and keep it away from heat and moisture.
In damp UK homes store medication in a bedroom cupboard rather than a bathroom to avoid humidity exposure.
Keep medicines in their original packaging and out of reach of children and pets.
- Avoid freezing and do not transfer medicines to unlabelled containers.
- Return out‑of‑date or unwanted medicines to a pharmacy for safe disposal.
Guidance from NHS and pharmacists
Pharmacists should check batch integrity, expiry date and correct packaging during dispensing.
For oral suspension ensure patients have an appropriate measuring device and understand storage instructions printed on the bottle.
Consider providing a printable quick‑reference card that lists storage, emergency contacts and Yellow Card reporting information.
Guidelines for proper use (practical counselling)
UK pharmacist counselling style
Counselling should be structured, person‑centred and cover the indication, dose, expected benefit timetable and common and serious side effects.
Discuss interactions, driving advice and pregnancy or breastfeeding considerations at the point of supply.
- Cover the dosing schedule and missed‑dose rules during counselling.
- Explain the tapering plan and schedule follow‑up contact or review.
- Advise when to seek urgent care for suicidal thoughts, serotonin syndrome or significant bleeding.
Document the counselling in the patient record and arrange a follow‑up where appropriate.
NHS patient safety advice
Stress the importance of adherence, avoiding abrupt stopping and attending scheduled follow‑ups.
For long‑term treatment schedule medication reviews and discuss deprescribing plans as clinically appropriate.
Provide clear signposting to urgent GP and mental health services for worsening mood or suicidality and NHS 111 out of hours.
Encourage reporting of side effects through the Yellow Card system to help monitor safety in the community.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Liverpool | England | 9–21 days |
| Newcastle | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Bristol | England | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
For any prescription changes or suspected adverse reactions contact your GP or pharmacist promptly.
Report serious suspected adverse reactions to the MHRA Yellow Card scheme to support national safety monitoring.